One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetes patients: a randomized, controlled trial
In Diabetes Care, 2008
... has received grants from Bristol Myers Squibb, Amylin, Eli Lilly, Novartis, Pfizer, Takeda, Roche, and Merck; participates in the speaker's ... Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
In Diabetes Care, 2006
... Lilly, Novartis, Pfizer, Takeda, Roche, and Johnson & Johnson and grant support from Bristol-Myers Squibb, Amylin, Eli Lilly, Novartis, Pfizer, Takeda, Roche, and Merck. Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndromemore suppliers
In Diabetes, 2004
... has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals, Arisaph Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Glenmark Pharmaceuticals, Hoffman LaRoche, Isis Pharmaceuticals, Merck Research Laboratories, Metabolex, Novartis ...
The impact of diabetes and diabetes medications on bone health.
More papers using
Orlando, United States. In Endocr Rev, Apr 2015
Animal models also have demonstrated a role for amylin in bone metabolism, but clinical trials in patients with type 1 diabetes with an amylin analog (pramlintide) have not shown a significant impact on bone metabolism.